Announced Thu, 9 Jul · 09:18 IST
Semaglutide batch quality issue delays Dr Reddys supplies
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-7.7%1-day move
₹1351.10
prior close
₹1332.90
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.6-0.6+0.7+0.6-7.7-8.5-7.8-9.0-9.3-9.6————
Up moveDown movePending
AI summary
Dr Reddys says some batches of semaglutide, a metabolic therapy drug, failed quality checks due to an issue with the active pharmaceutical ingredient. The company is investigating the root cause. Commercial supplies of the drug will be delayed until the issue is fixed. No impact on patient safety or existing global regulatory approvals. Management will hold a conference call today at 4:30 PM IST to discuss.
Likely market impact
Short term supply delay in a key metabolic drug could pressure near term sales until the issue is resolved.